CHRYSALIS Study Shows Potential of Amivantamab/Lazertinib in EGFRm NSCLC

Se-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study (NCT02609776) of amivantamab (Rybrevant) and lazertinib (Leclaza) in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

In the first-in-human, open-label, dose-escalation, phase 1 CHRYSALIS study, 20 treatment-naive patients with NSCLC harboring an EGFR mutation were evaluated to assess the safety, pharmacokinetics, and preliminary efficacy of the combination of amivantamab and lazertinib. Patients were required to be aged 18 years and older and have an ECOG performance status of 0-1.

According to long-term follow-up data from the CHRYSALIS study, patients treated with 1050 mg (1400 mg if ≥ 80 kg) of amivantamab and 240 mg of lazertinib had an overall response rate (ORR) of 100%. Additionally, all patients acheived a partial response on the combination therapy. However, any discussion on long-term results was limited due to the shorter follow-up.

Transcription:

0:10 | This is the era of targeted therapy and immuno-oncology. I'm conducting translational research for [patients with] lung cancer, especially focused on immuno-oncology or targeted therapy such as [targeting the] EGFR mutation. In Asia, EGFR mutations have very high prevalence [among patients with] lung cancer.

0:43 | For the introduction of the CHRSYALIS trial, we looked at the first-line treatment for treatment naive patients with amivantamab and lazertinib for patients with EGFR-NSCLC. [This research was] reported in a previous academic meeting, [which showed an] objective response rate of 100%. [It was a smaller patient population, but] a 100% response rate was fascinating. [However], for every clinician their concern is about the long-term follow-up of the research. After nearly 3 years [of follow up] the ORR was still 100%, and half of the patients remain disease-free and alive. This is also happy news for patients with EGFR-mutated NSCLC.